Micafungin (Synonyms: FK463)

Cat. No.: HY-17579: Data Sheet Handling Instructions Technical Support

Micafungin (Mycamine; FK463) is an echinocandin antifungal drug which can inhibit 1,3-beta-D-glucan synthase.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Micafungin sodium) that retains the same biological activity.

For research use only. We do not sell to patients.

Micafungin Chemical Structure

CAS No. : 235114-32-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

Other In-stock Forms of Micafungin:

Micafungin sodium

Other Forms of Micafungin:

Micafungin sodium In-stock

16 Publications Citing Use of MCE Micafungin

Featured Recommendations

•Related Small Molecules:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

Micafungin (Mycamine; FK463) is an echinocandin antifungal drug which can inhibit 1,3-beta-D-glucan synthase.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00606268	Astellas Pharma Inc	Fungal Infections	November 2007	Phase 1
NCT00809887	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Catheter-Related Fungal Infections	June 2006	Phase 1
NCT00839540	Gary E. Stein, Pharm.D.\|Astellas Pharma US, Inc.\|Michigan State University	Candidemia	December 2008	Phase 4
NCT00001937	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Aspergillosis\|Candidiasis\|Fungemia\|Mycoses	November 1999	Phase 3
NCT00665639	Astellas Pharma Inc	Candidiasis, Oral	June 2004	Phase 3
NCT00794703	Astellas Pharma Inc	Fungemia\|Fungal Infections	November 2008	Phase 3
NCT02244606	Scynexis, Inc.	Mycoses\|Candidiasis, Invasive\|Candidemia	September 2014	Phase 2
NCT03102658	Radboud University Medical Center\|St. Antonius Hospital\|Astellas Pharma Inc	Morbid Obesity	January 2017	Phase 4
NCT04728971	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Liver Transplantation	October 1, 2022	Phase 4
NCT02646800	Astellas Pharma China, Inc.\|Astellas Pharma Inc	Aspergillosis\|Candidiasis	March 21, 2014	Phase 4
NCT00036166	Astellas Pharma Inc	Aspergillosis	January 29, 1999	Phase 2
NCT04738955	Shandong Provincial Hospital	Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease	February 1, 2021	Phase 4
NCT01783379	Radboud University Medical Center	Invasive Fungal Infection	January 2013
NCT00608335	Astellas Pharma Inc	Oropharyngeal Candidiasis\|Candidemia\|Invasive Candidiasis\|Esophageal Candidiasis	October 14, 2007	Phase 1
NCT00666185	Astellas Pharma Inc	Candidiasis, Oral	August 2003	Phase 3
NCT00304772	Kyoto University\|Pfizer\|Astellas Pharma Inc\|Kyoto University Hospital	Candidiasis\|Sepsis	August 2006	Phase 4
NCT00106288	Astellas Pharma Inc	Candidiasis	January 2003	Phase 3
NCT02057289	Children´s Hospital Medical Center, Cincinnati\|Astellas Pharma Inc	Immunocompromised\|Bone Marrow Transplant\|Cancer	January 2014	Phase 1
NCT01666769	Kevin Watt\|Duke University	Invasive Candidiasis	January 2013	Phase 1
NCT02678598	Astellas Pharma China, Inc.\|Astellas Pharma Inc	Invasive Fungal Infections	March 2015
NCT00047827	Astellas Pharma Inc	Aspergillosis	December 2002	Phase 2
NCT01982071	Astellas Pharma China, Inc.\|Astellas Pharma Inc	Candidemia\|Candidiasis	September 26, 2013	Phase 4
NCT03421002	Astellas Pharma Global Development, Inc.\|IRCCS, Ospedale Pediatrico Bambino Gesu\|Astellas Pharma Inc	Candidiasis, Systemic\|Candida Meningitis	May 30, 2015	Phase 2
NCT02172768	Radboud University Medical Center	Acute Graft Versus Host Disease Grade II-IV\|Allogeneic Stem Cell Transplant\|Acute Myeloid Leucaemia\|Myelo Dysplastic Syndrome	October 2014	Phase 2
NCT03174457	Astellas Pharma Singapore Pte. Ltd.\|Astellas Pharma Inc	Invasive Fungal Infections	June 21, 2017
NCT01344681	Yonsei University	Febrile Neutropenia\|Hematological Diseases	June 2011	Phase 2
NCT00818584	Astellas Pharma Inc	Candida	August 2007	Phase 1
NCT01207128	University of Arkansas	Aspergillosis	February 2011	Phase 2
NCT02127788	Astellas Pharma S.A.S.\|Astellas Pharma Inc	Antifungal Prophylaxis\|Haemopathy	July 3, 2014
NCT01058174	Astellas Pharma Inc	Liver Transplantation\|Mycoses	December 15, 2009	Phase 3
NCT03906916	Fadoi Foundation, Italy	Invasive Candidiasis	July 18, 2018	Phase 4
NCT01686607	Astellas Pharma Europe B.V.\|World Health Information Science Consultants, LLC\|Astellas Pharma Inc	Systemic Fungal Infections	October 1, 2012
NCT00717860	Merck Sharp & Dohme LLC	Fungal Infection	August 2008	Phase 3
NCT00048750	Astellas Pharma Inc	Invasive Fungal Infections	January 2003	Phase 3
NCT00105144	Astellas Pharma Inc	Candidiasis\|Candidemia	September 2004	Phase 3
NCT00001790	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Fever\|Mycoses\|Neutropenia	October 1998	Phase 1
NCT01200355	Memorial Sloan Kettering Cancer Center\|Astellas Pharma US, Inc.	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	September 9, 2010	Phase 4
NCT05784844	Wake Forest University Health Sciences	Febrile Neutropenia	September 2023	Phase 4
NCT00815516	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Candidiasis	February 2013	Phase 3
NCT02164890	University Hospital, Limoges	Invasive Candidiasis	June 2014	Phase 4
NCT01122368	Astellas Pharma Inc	Mycoses	July 13, 2010	Phase 2
NCT01974375	Asan Medical Center	Liver Transplant Recipient	August 2012	Phase 3
NCT01135589	Asan Medical Center\|Astellas Pharma Korea, Inc.	Neutropenia\|Hematopoietic Stem Cell Transplantation\|Invasive Fungal Disease	April 2010	Phase 4
NCT01950507	National Institutes of Health Clinical Center (CC)\|National Heart, Lung, and Blood Institute (NHLBI)	Stem Cell Transplantation\|Graft vs Host Disease	February 20, 2014	Phase 1
NCT01773876	University Hospital, Grenoble	Invasive Candidiasis	July 2012	Phase 3
NCT05496725	Yung Shin Pharm. Ind. Co., Ltd.	Invasive Candidiasis	January 6, 2022	Phase 4
NCT01090141	University of Texas Southwestern Medical Center\|Astellas Pharma US, Inc.	Obesity\|Nutrition Disorders\|Overweight	November 2009	Phase 4
NCT02646774	Astellas Pharma China, Inc.\|Astellas Pharma Inc	Invasive Aspergillosis	March 1, 2014	Phase 4
NCT01888458	Nantes University Hospital	Invasive Fungal Infection	September 2013	Phase 2
NCT00607763	Astellas Pharma Inc	Invasive Candidiasis\|Esophageal Candidiasis\|Oropharyngeal Candidiasis\|Candidemia	October 2007	Phase 1
NCT00376337	Astellas Pharma Inc	Invasive Aspergillosis	June 2006	Phase 2
NCT00189709	Astellas Pharma Inc\|Astellas Pharma Taiwan, Inc.	Invasive Candidiasis\|Candidemia	August 2004	Phase 3
NCT00036179	Astellas Pharma Inc	Candidiasis	February 27, 1999	Phase 2
NCT00842504	Children´s Hospital Medical Center, Cincinnati\|Astellas Pharma Inc	Fungal Infection	July 2007	Phase 1
NCT02145832	Institut National de la Santé Et de la Recherche Médicale, France	Candidiasis	June 2014	Phase 2\|Phase 3
NCT02651038	Medical University of Vienna	Candida Sepsis	May 2012	Phase 4
NCT00423163	Astellas Pharma Inc	Aspergillosis+Blood\|Aspergillosis+Invasive	February 2007	Phase 4
NCT01417169	Seoul National University Hospital	Neutropenia\|Fungal Disease	August 2011	Phase 2
NCT02440178	Seoul National University Hospital\|Astellas Pharma Inc	Acute Leukemia	September 19, 2015	Phase 2

Molecular Weight

1270.27

Formula

C₅₆H₇₁N₉O₂₃S

CAS No.

235114-32-6

SMILES

O=C([C@](NC(C(NC([C@@](C[C@@H](O)C1)([H])N1C2=O)=O)[C@H](O)[C@H](C3=CC(OS(=O)(O)=O)=C(O)C=C3)O)=O)([H])[C@H](O)CC(N)=O)N4[C@@](C(N[C@@H]([C@@H](C[C@@H](C(NC2[C@H](O)C)=O)NC(C5=CC=C(C6=NOC(C7=CC=C(OCCCCC)C=C7)=C6)C=C5)=O)O)O)=O)([H])[C@@H](O)[C@@H](C)C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Data Sheet (269 KB) Handling Instructions (2659 KB)

References

[1]. Micafungin, From Wikipedia

Micafungin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Keywords:

Micafungin235114-32-6FK463FK 463FK-463FungalAntibioticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *